Navigation Links
NDIS Approval of the Promega PowerPlex(R) Y23 System Enables More Usable Profiles in Less Time
Date:2/5/2013

ng innovative solutions and technical support to the life sciences industry. The company’s 2,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit http://www.promega.com.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10394137.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
2. Watsons Generic Yaz(R) Receives FDA Approval
3. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
4. FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length
5. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
6. Watsons Generic BONIVA® 150mg Receives FDA Approval
7. Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors
8. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
9. FDA Issues Orphan Status Approval for PermaDerm®
10. West Wireless Health Institute Applauds House Passage of Bill to Streamline FDA Medical Device Approval Process, Expedite Mobile Medical App Guidance
11. Lupin Receives FDA Approval for Generic LYRICA(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... NEW YORK , May 22, 2013 /PRNewswire/ ... pioneering the development of disease modifying therapeutics for ... today the completion of its Series B financing, ... shares and warrants that would represent approximately $2.8M ... investors and new investors supported the raise. ...
(Date:5/22/2013)... N.H. , May 22, 2013  Superior ... the Year 2013" by Business NH Magazine.  For ... Granite State organizations that distinguish themselves with extraordinary ... very proud to receive this honor," said ... Controls.  "As with any recognition, this award is ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Genedata, ... industrial biotechnology, drug discovery, and life science research, ... Selector ™ as its bioinformatics platform for ... organisms. Genedata will provide AB Enzymes, one of ... a hosted solution of Genedata Selector accompanied by ...
(Date:5/22/2013)... 22, 2013 AudioNotch ... for tinnitus treatment. AudioNotch is pleased to announce ... clinic locations in both British Columbia and Alberta, ... and hearing services. AudioNotch's tinnitus treatment program is ... entering a Destination Hearing clinic, patients have the ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2
... on QuatRx clinical development programs, including review of positive results ... ... ANN ARBOR, Mich., Jan. 4 QuatRx Pharmaceuticals Company,today announced that ... presenter at the 26th Annual JP Morgan Healthcare,Conference on Tuesday, January ...
... the Company has been invited and has accepted to ... January 7-10, 2008 at,the Westin St. Francis Hotel in ... Chief Executive Officer will provide an,overview of the Company ... About JPMorgan 26th Annual Healthcare Conference, JPMorgan,s premier ...
... safety and efficacy in treatment of multi-drug ... resistant infections ... or the "Company"), a biopharmaceutical company focused on the,development of novel ... the first patients in two,separate Phase 2 clinical trials. The studies ...
Cached Biology Technology:QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 3
(Date:5/21/2013)... ANN ARBORThe new University of Michigan Water Center ... to support Great Lakes restoration and protection efforts. ... will support diverse projects, including efforts to track ... effectiveness of techniques to control non-native weedy plant ... and monitor fish responses to restoration activities. , ...
(Date:5/21/2013)... scientists have developed many devices that can reopen clogged ... effective, each of these treatments has drawbacks, including the ... MIT analyzes the potential usefulness of a new treatment ... stents, but may pose fewer risks. With this new ... only a brief period, during which it releases a ...
(Date:5/20/2013)... are also commonly resistant to antimicrobial substances made ... in mBio , the online open-access journal ... colistin and host antimicrobials LL-37 and lysozyme, which ... mean that patients with life-threatening multi-drug resistant infections ... Colistin is a last-line drug for treating several ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... Montral, June 23, 2009 On June 18, the ... $9.16 million for the creation of a national technology ... platform, headed by Dr. Benoit Coulombe from the Institut ... provide Canadian researchers with new state-of-the-art equipment in proteomics, ...
... 2009) University of Minnesota Medical School researchers have discovered an ... to treat those infected by a parasitic flatworm. ... The Schistosomasis parasite infects about 200 million people in ... where people become infected simply by bathing, drinking, or cooking water ...
... whips up more powerful and frequent hurricanes and storms, the ... breed and recover from damage. That,s one of the ... corals in the wake of large climate-driven bleaching and storm ... the regrowth of young corals drops sharply in ...
Cached Biology News:A Canada-wide technology platform for mapping the human interactome 2U of M study finds new insight on therapy for a devastating parasitic disease 2Coral face 'a stormy future' 2
... The IEC Centra CL3 series ... in typical research and clinical applications ... broad accessory package includes quick connect ... An advanced yet intuitive interface allows ...
PP2B-Abeta (C-20)...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... H2OBIT™ is a fully licensed, high throughput, water ... of up to 24 microplates. This equates to ... A robotic arm rapidly transfers a ... in temperature ramping times that are considerably faster ...
Biology Products: